- Home
- SLN vs SDHI Comparison
SLN vs SDHI Comparison
Compare SLN & SDHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | SDHI |
|---|---|---|
| Founded | 1994 | 2024 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 358.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | SLN | SDHI |
|---|---|---|
| Price | $5.01 | $10.27 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $39.67 | N/A |
| AVG Volume (30 Days) | ★ 355.5K | 170.2K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,830,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.39 | N/A |
| 52 Week Low | $1.97 | $10.00 |
| 52 Week High | $7.78 | $10.45 |
Technical Indicators
Market Signals| Indicator | SLN | SDHI |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 52.64 |
| Support Level | $4.88 | $10.25 |
| Resistance Level | $6.13 | $10.30 |
| Average True Range (ATR) | 0.51 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 10.40 | 62.50 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About SDHI Siddhi Acquisition Corp
Siddhi Acquisition Corp is a blank check company.